Interleukin-2 and regulatory T cells in rheumatic diseases.
Journal
Nature reviews. Rheumatology
ISSN: 1759-4804
Titre abrégé: Nat Rev Rheumatol
Pays: United States
ID NLM: 101500080
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
accepted:
30
09
2021
pubmed:
4
11
2021
medline:
22
1
2022
entrez:
3
11
2021
Statut:
ppublish
Résumé
Failure of regulatory T (T
Identifiants
pubmed: 34728817
doi: 10.1038/s41584-021-00707-x
pii: 10.1038/s41584-021-00707-x
doi:
Substances chimiques
Interleukin-2
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
749-766Informations de copyright
© 2021. Springer Nature Limited.
Références
Campbell, C. & Rudensky, A. Roles of regulatory T cells in tissue pathophysiology and metabolism. Cell Metab. 31, 18–25 (2020).
pubmed: 31607562
Morgan, D. A., Ruscetti, F. W. & Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007–1008 (1976).
pubmed: 181845
Taniguchi, T. et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302, 305–310 (1983).
pubmed: 6403867
Malek, T. R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153–165 (2010).
pubmed: 20732639
pmcid: 2946796
Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294 (2015).
pubmed: 25882245
Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018).
pubmed: 29980618
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).
pubmed: 16227984
Knoechel, B., Lohr, J., Kahn, E., Bluestone, J. A. & Abbas, A. K. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202, 1375–1386 (2005).
pubmed: 16287710
pmcid: 2212975
Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).
pubmed: 18468463
pmcid: 2394854
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151–1164 (1995).
pubmed: 7636184
Fuchs, A. et al. Minimum information about T regulatory cells: a step toward reproducibility and standardization. Front. Immunol. 8, 1844 (2017).
pubmed: 29379498
Jonuleit, H. et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193, 1285–1294 (2001).
pubmed: 11390435
pmcid: 2193380
Piccirillo, C. A. & Shevach, E. M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16, 81–88 (2004).
pubmed: 15036231
Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203, 1701–1711 (2006).
pubmed: 16818678
pmcid: 2118339
Li, W., Deng, C., Yang, H. & Wang, G. The regulatory T cell in active systemic lupus erythematosus patients: a systemic review and meta-analysis. Front. Immunol. 10, 159 (2019).
pubmed: 30833946
pmcid: 6387904
Yang, H. X. et al. Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells? Arthritis Res. Ther. 11, R153 (2009).
pubmed: 19821980
pmcid: 2787292
Sharabi, A. et al. Regulatory T cells in the treatment of disease. Nat. Rev. Drug Discov. 17, 823–844 (2018).
pubmed: 30310234
Christoffersson, G. & von Herrath, M. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol. 40, 482–491 (2019).
pubmed: 31101537
Churlaud, G. et al. Human and mouse CD8(+)CD25(+)FOXP3(+) regulatory T cells at steady state and during interleukin-2 therapy. Front. Immunol. 6, 171 (2015).
pubmed: 25926835
pmcid: 4397865
Chaput, N. et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58, 520–529 (2009).
pubmed: 19022917
Roncarolo, M. G., Gregori, S., Bacchetta, R., Battaglia, M. & Gagliani, N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity 49, 1004–1019 (2018).
pubmed: 30566879
Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749–769 (2019).
pubmed: 31541224
pmcid: 7773144
Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018).
pubmed: 30089912
Guo, H. et al. Functional defects in CD4(+) CD25(high) FoxP3(+) regulatory cells in ankylosing spondylitis. Sci. Rep. 6, 37559 (2016).
pubmed: 27901054
pmcid: 5128857
Wang, J. et al. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Ther. Adv. Chronic Dis. 11, 2040622320916014 (2020).
pubmed: 32523664
pmcid: 7236566
Haufe, S. et al. Impaired suppression of synovial fluid CD4+CD25- T cells from patients with juvenile idiopathic arthritis by CD4+CD25+ Treg cells. Arthritis Rheum. 63, 3153–3162 (2011).
pubmed: 21702013
Frantz, C., Auffray, C., Avouac, J. & Allanore, Y. Regulatory T cells in systemic sclerosis. Front. Immunol. 9, 2356 (2018).
pubmed: 30374354
pmcid: 6196252
Slobodin, G. & Rimar, D. Regulatory T cells in systemic sclerosis: a comprehensive review. Clin. Rev. Allergy Immunol. 52, 194–201 (2017).
pubmed: 27318947
Grunewald, J. et al. Sarcoidosis. Nat. Rev. Dis. Prim. 5, 45 (2019).
pubmed: 31273209
Powell, J. D., Ragheb, J. A., Kitagawa-Sakakida, S. & Schwartz, R. H. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol. Rev. 165, 287–300 (1998).
pubmed: 9850868
Smigiel, K. S. et al. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J. Exp. Med. 211, 121–136 (2014).
pubmed: 24378538
pmcid: 3892972
O’Gorman, W. E. et al. The initial phase of an immune response functions to activate regulatory T cells. J. Immunol. 183, 332–339 (2009).
pubmed: 19542444
Liu, Z. et al. Immune homeostasis enforced by co-localized effector and regulatory T cells. Nature 528, 225–230 (2015).
pubmed: 26605524
pmcid: 4702500
Yu, A. et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64, 2172–2183 (2015).
pubmed: 25576057
Yu, A., Zhu, L., Altman, N. H. & Malek, T. R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204–217 (2009).
pubmed: 19185518
pmcid: 2962446
Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061 (2003).
pubmed: 12522256
Nelson, B. H. & Willerford, D. M. Biology of the interleukin-2 receptor. Adv. Immunol. 70, 1–81 (1998).
pubmed: 9755337
Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13–25 (2013).
pubmed: 23352221
pmcid: 3610532
Arenas-Ramirez, N., Woytschak, J. & Boyman, O. Interleukin-2: biology, design and application. Trends Immunol. 36, 763–777 (2015).
pubmed: 26572555
Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A. & Wilson, I. A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl Acad. Sci. USA 103, 2788–2793 (2006).
pubmed: 16477002
pmcid: 1413841
Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190 (2012).
pubmed: 22343569
Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74–88 (2020).
pubmed: 31686003
Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843–862 (2017).
pubmed: 29104284
Hemar, A. et al. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J. Cell Biol. 129, 55–64 (1995).
pubmed: 7698995
Muller, M. R. & Rao, A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol. 10, 645–656 (2010).
pubmed: 20725108
Burzyn, D., Benoist, C. & Mathis, D. Regulatory T cells in nonlymphoid tissues. Nat. Immunol. 14, 1007–1013 (2013).
pubmed: 24048122
pmcid: 4708287
Michalek, R. D. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186, 3299–3303 (2011).
pubmed: 21317389
Kim, H. P., Imbert, J. & Leonard, W. J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor. Rev. 17, 349–366 (2006).
pubmed: 16911870
Walsh, P. T. et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J. Clin. Invest. 116, 2521–2531 (2006).
pubmed: 16917540
pmcid: 1550279
Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252–256 (2013).
pubmed: 23913274
pmcid: 3867145
Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).
pubmed: 18845758
Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
pubmed: 21474713
pmcid: 3198051
Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257–1265 (2007).
pubmed: 17502665
pmcid: 2118603
Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322–1333 (2016).
pubmed: 27595233
pmcid: 5071159
Busse, D. et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc. Natl Acad. Sci. USA 107, 3058–3063 (2010).
pubmed: 20133667
pmcid: 2840293
Gondek, D. C., Lu, L. F., Quezada, S. A., Sakaguchi, S. & Noelle, R. J. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174, 1783–1786 (2005).
pubmed: 15699103
Cao, X. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635–646 (2007).
pubmed: 17919943
Barron, L. et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J. Immunol. 185, 6426–6430 (2010).
pubmed: 21037099
Asano, T. et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood 129, 2186–2197 (2017).
pubmed: 28151427
pmcid: 5391624
Park, H. J. et al. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol. 278, 76–83 (2012).
pubmed: 23121978
Konopacki, C., Pritykin, Y., Rubtsov, Y., Leslie, C. S. & Rudensky, A. Y. Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function. Nat. Immunol. 20, 232–242 (2019).
pubmed: 30643266
pmcid: 7534899
Scheinecker, C., Goschl, L. & Bonelli, M. Treg cells in health and autoimmune diseases: new insights from single cell analysis. J. Autoimmun. 110, 102376 (2020).
pubmed: 31862128
Chen, X. & Oppenheim, J. J. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology 133, 426–433 (2011).
pubmed: 21631498
pmcid: 3143354
Zaragoza, B. et al. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat. Med. 22, 16–17 (2016).
pubmed: 26735402
pmcid: 6345394
Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R. & Okkenhaug, K. The PI3K p110δ regulates expression of CD38 on regulatory T cells. PLoS ONE 6, e17359 (2011).
pubmed: 21390257
pmcid: 3046981
Krejcik, J. et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384–394 (2016).
pubmed: 27222480
pmcid: 4957162
Burkett, P. R., Meyer zu Horste, G. & Kuchroo, V. K. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J. Clin. Invest. 125, 2211–2219 (2015).
pubmed: 25961452
pmcid: 4497747
Zielinski, C. E. et al. Pathogen-induced human TH17 cells produce IFN-ɣ or IL-10 and are regulated by IL-1β. Nature 484, 514–518 (2012).
pubmed: 22466287
Stockinger, B. & Omenetti, S. The dichotomous nature of T helper 17 cells. Nat. Rev. Immunol. 17, 535–544 (2017).
pubmed: 28555673
Liao, W., Lin, J. X., Wang, L., Li, P. & Leonard, W. J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12, 551–559 (2011).
pubmed: 21516110
pmcid: 3304099
Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371–381 (2007).
pubmed: 17363300
Yang, X. P. et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12, 247–254 (2011).
pubmed: 21278738
pmcid: 3182404
Ballesteros-Tato, A. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36, 847–856 (2012).
pubmed: 22464171
pmcid: 3361521
Li, J., Lu, E., Yi, T. & Cyster, J. G. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature 533, 110–114 (2016).
pubmed: 27147029
pmcid: 4883664
Oestreich, K. J., Mohn, S. E. & Weinmann, A. S. Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nat. Immunol. 13, 405–411 (2012).
pubmed: 22406686
pmcid: 3561768
Oestreich, K. J. et al. Bcl-6 directly represses the gene program of the glycolysis pathway. Nat. Immunol. 15, 957–964 (2014).
pubmed: 25194422
pmcid: 4226759
Wing, J. B., Tekguc, M. & Sakaguchi, S. Control of germinal center responses by T-follicular regulatory cells. Front. Immunol. 9, 1910 (2018).
pubmed: 30197643
pmcid: 6117393
Ritvo, P. G. et al. Tfr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells. Sci. Immunol. 2, eaan0368 (2017).
pubmed: 28887367
Deng, J., Wei, Y., Fonseca, V. R., Graca, L. & Yu, D. T follicular helper cells and T follicular regulatory cells in rheumatic diseases. Nat. Rev. Rheumatol. 15, 475–490 (2019).
pubmed: 31289377
Panduro, M., Benoist, C. & Mathis, D. Tissue Tregs. Annu. Rev. Immunol. 34, 609–633 (2016).
pubmed: 27168246
pmcid: 4942112
Hovhannisyan, Z., Treatman, J., Littman, D. R. & Mayer, L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 140, 957–965 (2011).
pubmed: 21147109
Malhotra, N. et al. RORα-expressing T regulatory cells restrain allergic skin inflammation. Sci. Immunol. 3, eaao6923 (2018).
pubmed: 29500225
pmcid: 5912895
Delacher, M. et al. Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues. Nat. Immunol. 18, 1160–1172 (2017).
pubmed: 28783152
pmcid: 5912503
Feuerer, M., Hill, J. A., Mathis, D. & Benoist, C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 10, 689–695 (2009).
pubmed: 19536194
Ali, N. et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell 169, 1119–1129.e11 (2017).
pubmed: 28552347
pmcid: 5504703
Hirata, Y. et al. CD150(high) bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine. Cell Stem Cell 22, 445–453.e5 (2018).
pubmed: 29456159
pmcid: 6534147
Fujisaki, J. et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474, 216–219 (2011).
pubmed: 21654805
pmcid: 3725645
Li, J., Tan, J., Martino, M. M. & Lui, K. O. Regulatory T-cells: potential regulator of tissue repair and regeneration. Front. Immunol. 9, 585 (2018).
pubmed: 29662491
pmcid: 5890151
Burzyn, D. et al. A special population of regulatory T cells potentiates muscle repair. Cell 155, 1282–1295 (2013).
pubmed: 24315098
pmcid: 3894749
Villalta, S. A. et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 6, 258ra142 (2014).
pubmed: 25320234
pmcid: 4889432
Sharma, A. & Rudra, D. Emerging functions of regulatory T cells in tissue homeostasis. Front. Immunol. 9, 883 (2018).
pubmed: 29887862
pmcid: 5989423
Arpaia, N. et al. A distinct function of regulatory T cells in tissue protection. Cell 162, 1078–1089 (2015).
pubmed: 26317471
pmcid: 4603556
Zaiss, D. M. W., Gause, W. C., Osborne, L. C. & Artis, D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42, 216–226 (2015).
pubmed: 25692699
pmcid: 4792035
Boothby, M. Signaling in T cells–is anything the m(a)TOR with the picture(s)? F1000Res. 5, 191 (2016).
Sharabi, A. & Tsokos, G. C. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat. Rev. Rheumatol. 16, 100–112 (2020).
pubmed: 31949287
Angelin, A. et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 25, 1282–1293.e7 (2017).
pubmed: 28416194
pmcid: 5462872
Zeng, H. & Chi, H. Metabolic control of regulatory T cell development and function. Trends Immunol. 36, 3–12 (2015).
pubmed: 25248463
De Rosa, V. et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat. Immunol. 16, 1174–1184 (2015).
pubmed: 26414764
pmcid: 4868085
Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).
pubmed: 23828891
Yang, X. O. et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29, 44–56 (2008).
pubmed: 18585065
pmcid: 2630532
Takeuchi, Y., Hirota, K. & Sakaguchi, S. Synovial tissue inflammation mediated by autoimmune T cells. Front. Immunol. 10, 1989 (2019).
pubmed: 31497022
pmcid: 6712680
Alexander, T. et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann. Rheum. Dis. 72, 1549–1558 (2013).
pubmed: 23264341
Golding, A., Hasni, S., Illei, G. & Shevach, E. M. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. 65, 2898–2906 (2013).
pubmed: 23925905
pmcid: 3891045
Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Prim. 4, 18001 (2018).
pubmed: 29417936
Malmstrom, V., Catrina, A. I. & Klareskog, L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat. Rev. Immunol. 17, 60–75 (2017).
pubmed: 27916980
McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).
pubmed: 22150039
Humby, F. et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 6, e1 (2009).
pubmed: 19143467
pmcid: 2621263
Ziff, M. Relation of cellular infiltration of rheumatoid synovial membrane to its immune response. Arthritis Rheum. 17, 313–319 (1974).
pubmed: 4545206
Kitas, G. D., Salmon, M., Farr, M., Gaston, J. S. & Bacon, P. A. Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications. Clin. Exp. Immunol. 73, 242–249 (1988).
pubmed: 2972426
pmcid: 1541612
von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407–1415 (2016).
Lieberman, L. A. & Tsokos, G. C. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. Biomed. Biotechnol. 2010, 740619 (2010).
pubmed: 20625413
pmcid: 2896881
Rosenzwajg, M. et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J. Autoimmun. 58, 48–58 (2015).
pubmed: 25634360
pmcid: 8153751
Morita, T. et al. The proportion of regulatory T cells in patients with rheumatoid arthritis: a meta-analysis. PLoS ONE 11, e0162306 (2016).
pubmed: 27622457
pmcid: 5021283
Cammarata, I. et al. Counter-regulation of regulatory T cells by autoreactive CD8(+) T cells in rheumatoid arthritis. J. Autoimmun. 99, 81–97 (2019).
pubmed: 30777378
Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).
pubmed: 22129255
Tsokos, G. C. Autoimmunity and organ damage in systemic lupus erythematosus. Nat. Immunol. 21, 605–614 (2020).
pubmed: 32367037
pmcid: 8135909
Humrich, J. Y. & Riemekasten, G. Restoring regulation–IL-2 therapy in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 12, 1153–1160 (2016).
pubmed: 27283871
Mizui, M. & Tsokos, G. C. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front. Immunol. 9, 786 (2018).
pubmed: 29755456
pmcid: 5932391
Ohl, K. & Tenbrock, K. Regulatory T cells in systemic lupus erythematosus. Eur. J. Immunol. 45, 344–355 (2015).
pubmed: 25378177
Tsokos, G. C., Lo, M. S., Costa Reis, P. & Sullivan, K. E. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat. Rev. Rheumatol. 12, 716–730 (2016).
pubmed: 27872476
Katsuyama, T., Tsokos, G. C. & Moulton, V. R. Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front. Immunol. 9, 1088 (2018).
pubmed: 29868033
pmcid: 5967272
Comte, D. et al. Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2. Arthritis Rheumatol. 69, 808–813 (2017).
pubmed: 27992687
pmcid: 5526072
Linker-Israeli, M. et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 130, 2651–2655 (1983).
pubmed: 6222112
Alcocer-Varela, J. & Alarcon-Segovia, D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 69, 1388–1392 (1982).
pubmed: 6979554
pmcid: 370212
Dauphinee, M. J., Kipper, S. B., Wofsy, D. & Talal, N. Interleukin 2 deficiency is a common feature of autoimmune mice. J. Immunol. 127, 2483–2487 (1981).
pubmed: 6975325
Humrich, J. Y. et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl Acad. Sci. USA 107, 204–209 (2010).
pubmed: 20018660
Koga, T. et al. CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. J. Clin. Invest. 124, 2234–2245 (2014).
pubmed: 24667640
pmcid: 4001553
Moulton, V. R., Grammatikos, A. P., Fitzgerald, L. M. & Tsokos, G. C. Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proc. Natl Acad. Sci. USA 110, 1845–1850 (2013).
pubmed: 23319613
pmcid: 3562779
Kyttaris, V. C., Juang, Y. T., Tenbrock, K., Weinstein, A. & Tsokos, G. C. Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 173, 3557–3563 (2004).
pubmed: 15322221
Costa, N. et al. Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives. Clin. Exp. Immunol. 189, 318–330 (2017).
pubmed: 28542701
pmcid: 5543470
Li, S. et al. Downregulation of IL-10 secretion by Treg cells in osteoarthritis is associated with a reduction in Tim-3 expression. Biomed. Pharmacother. 79, 159–165 (2016).
pubmed: 27044824
Moradi, B. et al. CD4(+)CD25(+)/highCD127low/(-) regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints–analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res. Ther. 16, R97 (2014).
pubmed: 24742142
pmcid: 4060198
Ranganathan, V., Gracey, E., Brown, M. A., Inman, R. D. & Haroon, N. Pathogenesis of ankylosing spondylitis – recent advances and future directions. Nat. Rev. Rheumatol. 13, 359–367 (2017).
pubmed: 28446810
Bravo, A. & Kavanaugh, A. Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. Nat. Rev. Rheumatol. 15, 645–656 (2019).
pubmed: 31485004
Appel, H. et al. Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. J. Rheumatol. 38, 2445–2451 (2011).
pubmed: 21921098
Copland, A. & Bending, D. Foxp3 molecular dynamics in Treg in juvenile idiopathic arthritis. Front. Immunol. 9, 2273 (2018).
pubmed: 30333832
pmcid: 6175987
Brito-Zerón, P. et al. Sjögren syndrome. Nat. Rev. Dis. Prim. 2, 16047 (2016).
pubmed: 27383445
Li, X. et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren’s syndrome. J. Rheumatol. 34, 2438–2445 (2007).
pubmed: 18050367
Alunno, A. et al. T regulatory and T helper 17 cells in primary Sjögren’s syndrome: facts and perspectives. Med. Inflamm. 2015, 243723 (2015).
Luo, J. et al. IL-2 inhibition of Th17 generation rather than induction of treg cells is impaired in primary Sjögren’s syndrome patients. Front. Immunol. 9, 1755 (2018).
pubmed: 30150979
pmcid: 6100298
Liu, C., Guan, Z., Zhao, L., Song, Y. & Wang, H. Elevated level of circulating CD4(+)Helios(+)FoxP3(+) cells in primary Sjögren’s syndrome patients. Mod. Rheumatol. 27, 630–637 (2017).
pubmed: 27538522
Alunno, A. et al. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren’s syndrome. Rheumatology 52, 1387–1396 (2013).
pubmed: 23674818
Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Prim. 1, 15002 (2015).
pubmed: 27189141
Koreth, J. et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 128, 130–137 (2016).
pubmed: 27073224
pmcid: 4937358
Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055–2066 (2011).
pubmed: 22129252
pmcid: 3727432
Morgan, M. D. et al. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 130, 64–73 (2010).
pubmed: 20113371
pmcid: 2855794
Tsurikisawa, N., Saito, H., Oshikata, C., Tsuburai, T. & Akiyama, K. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J. Clin. Immunol. 33, 965–976 (2013).
pubmed: 23624693
Tsurikisawa, N., Saito, H., Oshikata, C., Tsuburai, T. & Akiyama, K. High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis. Clin. Transl. Allergy 4, 38 (2014).
pubmed: 25937899
pmcid: 4417532
Boyer, O. et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 103, 3428–3430 (2004).
pubmed: 14684420
Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067–2077 (2011).
pubmed: 22129253
Shimojima, Y., Ishii, W., Kishida, D., Fukushima, K. & Ikeda, S. I. Imbalanced expression of dysfunctional regulatory T cells and T-helper cells relates to immunopathogenesis in polyarteritis nodosa. Mod. Rheumatol. 27, 102–109 (2017).
pubmed: 27142840
Sugita, S., Yamada, Y., Kaneko, S., Horie, S. & Mochizuki, M. Induction of regulatory T cells by infliximab in Behçet’s disease. Invest. Ophthalmol. Vis. Sci. 52, 476–484 (2011).
pubmed: 20861484
Olivito, B. et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin. Exp. Rheumatol. 28, 93–97 (2010).
pubmed: 20412712
Kong, X. et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin. Exp. Rheumatol. 34, S21–S27 (2016).
pubmed: 26633132
Samson, M. et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 64, 3788–3798 (2012).
pubmed: 22833233
Miyara, M. et al. The immune paradox of sarcoidosis and regulatory T cells. J. Exp. Med. 203, 359–370 (2006).
pubmed: 16432251
pmcid: 2118208
Broos, C. E. et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir. Res. 16, 108 (2015).
pubmed: 26376720
pmcid: 4574219
Verwoerd, A. et al. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis. Clin. Exp. Immunol. 185, 263–270 (2016).
pubmed: 27158798
pmcid: 4955009
So, A. K. & Martinon, F. Inflammation in gout: mechanisms and therapeutic targets. Nat. Rev. Rheumatol. 13, 639–647 (2017).
pubmed: 28959043
Dai, X. J. et al. Changes of Treg/Th17 ratio in spleen of acute gouty arthritis rat induced by MSU crystals. Inflammation 41, 1955–1964 (2018).
pubmed: 30039428
Bonnet, B. et al. Low-dose IL-2 induces regulatory T cell-mediated control of experimental food allergy. J. Immunol. 197, 188–198 (2016).
pubmed: 27259854
Churlaud, G. et al. Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2. J. Allergy Clin. Immunol. 142, 1344–1346.e3 (2018).
pubmed: 29920353
Churlaud, G. et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin. Immunol. 151, 114–126 (2014).
pubmed: 24576619
Tahvildari, M. & Dana, R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J. Immunol. 203, 2749–2755 (2019).
pubmed: 31740549
Rose, A. et al. IL-2 therapy diminishes renal inflammation and the activity of kidney-infiltrating CD4+ T cells in murine lupus nephritis. Cells https://doi.org/10.3390/cells8101234 (2019).
doi: 10.3390/cells8101234
pubmed: 31906100
pmcid: 7016939
Yan, J. J. et al. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells. Kidney Int. 91, 603–615 (2017).
pubmed: 27914701
Mizui, M. et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J. Immunol. 193, 2168–2177 (2014).
pubmed: 25063876
Crispin, J. C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181, 8761–8766 (2008).
pubmed: 19050297
Yokoyama, Y. et al. IL-2-anti-IL-2 monoclonal antibody immune complexes inhibit collagen-induced arthritis by augmenting regulatory T cell functions. J. Immunol. 201, 1899–1906 (2018).
pubmed: 30143591
Dey, I. & Bishayi, B. Impact of simultaneous neutralization of IL-17A and treatment with recombinant IL-2 on Th17-Treg cell population in S.aureus induced septic arthritis. Microb. Pathog. 139, 103903 (2020).
pubmed: 31790794
Bergmann, B. et al. Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice. BMC Infect. Dis. 20, 185 (2020).
pubmed: 32111171
pmcid: 7048135
Webster, K. E. et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751–760 (2009).
pubmed: 19332874
pmcid: 2715127
Izquierdo, C. et al. Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers. Sci. Rep. 8, 8106 (2018).
pubmed: 29802270
pmcid: 5970271
Taylor, A. E. et al. Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis. Hepatology 68, 1905–1921 (2018).
pubmed: 29698570
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
pubmed: 24907378
Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M. & Schwarz, S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161, 1169–1188 (1985).
pubmed: 3886826
Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253–261 (1993).
pubmed: 8402910
Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167–178 (2002).
pubmed: 12196288
Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209–217 (2019).
pubmed: 30472651
Mahmoudpour, S. H. et al. Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 9, 7145 (2019).
pubmed: 31073219
pmcid: 6509335
Humrich, J. Y. et al. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol. 1, e44–e54 (2019).
He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141–149 (2020).
pubmed: 31537547
Rosenzwajg, M. et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 63, 1808–1821 (2020).
pubmed: 32607749
Krouse, R. S. et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J. Immunother. Emphas. Tumor Immunol. 18, 272–278 (1995).
Churlaud, G. et al. IL-2 antibodies in type 1 diabetes and during IL-2 therapy. Diabetologia 61, 2066–2068 (2018).
pubmed: 29860627
Blattman, J. N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9, 540–547 (2003).
pubmed: 12692546
Hervier, B. et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-ɣ production in patients with active disease. Arthritis Rheum. 63, 1698–1706 (2011).
pubmed: 21370226
Busner, J. & Targum, S. D. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry 4, 28–37 (2007).
pubmed: 20526405
pmcid: 2880930
He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991–993 (2016).
pubmed: 27500725
Humrich, J. Y. et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74, 791–792 (2015).
pubmed: 25609413
Zhao, C. et al. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients. BMC Immunol. 20, 32 (2019).
pubmed: 31484501
pmcid: 6727508
Shao, M. et al. Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus. J. Interferon Cytokine Res. 39, 117–124 (2019).
pubmed: 30721117
Miao, M. et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome. Ann. Rheum. Dis. 77, 1838–1840 (2018).
pubmed: 29936436
An, H. et al. The absolute counts of peripheral T lymphocyte subsets in patient with ankylosing spondylitis and the effect of low-dose interleukin-2. Medicine 98, e15094 (2019).
pubmed: 30985663
pmcid: 6485794
Feng, M. et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int. Immunopharmacol. 77, 105912 (2019).
pubmed: 31669890
Zhang, S. X. et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216246 (2019).
doi: 10.1136/annrheumdis-2019-216246
pubmed: 31871141
Castela, E. et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 150, 748–751 (2014).
pubmed: 24872229
Le Duff, F. et al. Low-dose IL-2 for treating moderate to severe alopecia areata: a 52-week multicenter prospective placebo-controlled study assessing its impact on T regulatory cell and NK cell populations. J. Invest. Dermatol. 141, 933–936 (2021).
pubmed: 32941917
Zhang, J. et al. Therapeutic potential of low-dose IL-2 in immune thrombocytopenia: an analysis of 3 cases. Cytom. B Clin. Cytom. 94, 428–433 (2018).
Lim, T. Y. et al. Low-dose interleukin-2 for refractory autoimmune hepatitis. Hepatology 68, 1649–1652 (2018).
pubmed: 29698571
Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. 200, 277–285 (2004).
pubmed: 15280421
pmcid: 2211983
Nguyen, D. X. & Ehrenstein, M. R. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J. Exp. Med. 213, 1241–1253 (2016).
pubmed: 27270893
pmcid: 4925013
He, X. et al. A TNFR2-agonist facilitates high purity expansion of human low purity treg cells. PLoS ONE 11, e0156311 (2016).
pubmed: 27224512
pmcid: 4880213
Okubo, Y., Mera, T., Wang, L. & Faustman, D. L. Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci. Rep. 3, 3153 (2013).
pubmed: 24193319
pmcid: 3818650
Chopra, M. et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J. Exp. Med. 213, 1881–1900 (2016).
pubmed: 27526711
pmcid: 4995078
Chen, Z. et al. FOXP3 and RORɣt: transcriptional regulation of Treg and Th17. Int. Immunopharmacol. 11, 536–542 (2011).
pubmed: 21081189
Valencia, X. et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108, 253–261 (2006).
pubmed: 16537805
pmcid: 1895836
Tseng, W. Y. et al. TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells. Proc. Natl Acad. Sci. USA 116, 21666–21672 (2019).
pubmed: 31597740
pmcid: 6815167
Santinon, F. et al. Involvement of tumor necrosis factor receptor type II in FoxP3 stability and as a marker of Treg cells specifically expanded by anti-tumor necrosis factor treatments in rheumatoid arthritis. Arthritis Rheumatol. 72, 576–587 (2020).
pubmed: 31609517
Zhang, C., Zhang, X. & Chen, X. H. Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance. Clin. Rev. Allergy Immunol. 47, 163–173 (2014).
pubmed: 24647663
Schinnerling, K., Aguillon, J. C., Catalan, D. & Soto, L. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin. Exp. Immunol. 189, 12–20 (2017).
pubmed: 28369786
pmcid: 5461092
Thiolat, A. et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 66, 273–283 (2014).
pubmed: 24504799
Samson, M. et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 64, 2499–2503 (2012).
pubmed: 22488116
Kikuchi, J. et al. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res. Ther. 17, 10 (2015).
pubmed: 25604867
pmcid: 4332922
Takatori, H. et al. Helios enhances Treg cell function in cooperation with FoxP3. Arthritis Rheumatol. 67, 1491–1502 (2015).
pubmed: 25733061
Sheng-Xiao, Z. et al. SAT0181 Low dose interleukin-2 combined with tocilizumab selectively increases regulatory T cells helping refractory rheumatoid arthritis patients achieve remission more rapidly. Ann. Rheum. Dis. 76, 839 (2017).
Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299, 1033–1036 (2003).
pubmed: 12532024
Wan, S., Xia, C. & Morel, L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 178, 271–279 (2007).
pubmed: 17182564
Dai, H., He, F., Tsokos, G. C. & Kyttaris, V. C. IL-23 limits the production of IL-2 and promotes autoimmunity in lupus. J. Immunol. 199, 903–910 (2017).
pubmed: 28646040
Kannan, A. K. et al. IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases. Sci. Rep. 9, 17675 (2019).
pubmed: 31776355
pmcid: 6881359
Izcue, A. et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28, 559–570 (2008).
pubmed: 18400195
pmcid: 2292821
Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).
pubmed: 25043027
pmcid: 4339042
Nussbaum, L., Chen, Y. L. & Ogg, G. S. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br. J. Dermatol. 184, 14–24 (2021).
pubmed: 32628773
van Vollenhoven, R. F. et al. Maintenance of efficacy and safety of ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol. 72, 761–768 (2020).
pubmed: 31769212
Konrad, M. W. et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 50, 2009–2017 (1990).
pubmed: 2317789
Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680–690 (2016).
pubmed: 26832745
Trotta, E. et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat. Med. 24, 1005–1014 (2018).
pubmed: 29942088
pmcid: 6398608
Klein, C. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6, e1277306 (2017).
pubmed: 28405498
pmcid: 5384349
van Brummelen, E. M. J. et al. (89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding. Oncotarget 9, 24737–24749 (2018).
pubmed: 29872502
pmcid: 5973872
Weide, B. et al. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunol. Immunother. 68, 1547–1559 (2019).
pubmed: 31482307
Neri, D. & Sondel, P. M. Immunocytokines for cancer treatment: past, present and future. Curr. Opin. Immunol. 40, 96–102 (2016).
pubmed: 27060634
pmcid: 5215124
Padutsch, T. et al. Superior Treg-expanding properties of a novel dual-acting cytokine fusion protein. Front. Pharmacol. 10, 1490 (2019).
pubmed: 31920671
pmcid: 6930692
Peterson, L. B. et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J. Autoimmun. 95, 1–14 (2018).
pubmed: 30446251
pmcid: 6284106
Comte, D. et al. Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 113, 9321–9326 (2016).
pubmed: 27482100
pmcid: 4995972
Guma, S. R. et al. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr. Blood Cancer 61, 618–626 (2014).
pubmed: 24136885
Horwitz, D. A., Bickerton, S., Koss, M., Fahmy, T. M. & La Cava, A. Suppression of murine lupus by CD4+ and CD8+ Treg cells induced by T cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor β. Arthritis Rheumatol. 71, 632–640 (2019).
pubmed: 30407752
pmcid: 6438734
Siddhanti, S. et al. NKTR-358, a novel IL-2 conjugate, stimulates high levels of regulatory T cells in patients with systemic lupus erythematosus [abstract THU0054]. Ann. Rheum. Dis. 79, 238–239 (2020).
Pilat, N. et al. Treg-mediated prolonged survival of skin allografts without immunosuppression. Proc. Natl Acad. Sci. USA 116, 13508–13516 (2019).
pubmed: 31196957
pmcid: 6613183
Karakus, U. et al. Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. Sci. Transl. Med. 12, eabb9283 (2020).
pubmed: 33328333
Fischer, R. et al. Selective activation of tumor necrosis factor receptor II induces antiinflammatory responses and alleviates experimental arthritis. Arthritis Rheumatol. 70, 722–735 (2018).
pubmed: 29342501
Laurent, J. et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J. Transl. Med. 11, 5 (2013).
pubmed: 23294527
pmcid: 3551760